Change in symptom and quality of life in COPD by Budesonide/Glycopyrronium/Formoterol fumarate pressurized metered dose inhaler (BGF pMDI)

Trial Identifier: D5980R00033
Sponsor: AstraZeneca
NCTID:: NCT05219630
Start Date: May 2022
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Aichi Nagoya, Aichi, Japan, Nagoya
Japan, Aichi Seto, Aichi, Japan, Seto
Japan, Ehime Toon, Ehime, Japan, Toon
Japan, Fukui Fukui, Japan, Fukui
Japan, Fukuoka Fukuoka, Japan, Fukuoka
Japan, Fukuoka Kurume, Fukuoka, Japan, Kurume
Japan, Hiroshima Hiroshima, Japan, Hiroshima
Japan, Ibaraki Tsuchiura, Ibaraki, Japan, Tsuchiura
Japan, Ishikawa Kanazawa, Ishikawa, Japan, Kanazawa
Japan, Kagawa Takamatsu, Kagawa, Japan, Takamatsu
Japan, Kagoshima Kagoshima, Japan, Kagoshima
Japan, Mie Matsuzaka, Mie, Japan, Matsuzaka
Japan, Miyazaki Miyazaki, Japan, Miyazaki
Japan, Nara Kashihara, Nara, Japan, Kashihara
Japan, Oita Oita, Japan, Oita
Japan, Osaka Osaka, Japan, Osaka
Japan, Tokyo Chuo, Tokyo, Japan, Chuo